Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tizanidine
Drug ID BADD_D02230
Description Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Indications and Usage Tizanidine is indicated for the relief of muscle spasticity, which can interfere with daily activities. The general recommendation is to reserve tizanidine use for periods of time when there is a particular need for relief, as it has a short duration of action [FDA label, F4471].
Marketing Status approved; investigational
ATC Code M03BX02
DrugBank ID DB00697
KEGG ID D08611
MeSH ID C023754
PubChem ID 5487
TTD Drug ID D01MDT
NDC Product Code 72789-325; 35356-662; 50090-0840; 51655-740; 53002-1418; 57664-502; 60760-694; 70771-1335; 72578-096; 61919-221; 63187-009; 63187-910; 63629-8533; 68084-645; 29300-168; 29300-169; 42291-809; 55111-180; 60760-263; 63629-2371; 71610-228; 60760-505; 63187-493; 63187-673; 68084-775; 70518-3658; 71610-451; 0615-8468; 72578-097; 0904-6418; 43063-868; 60505-0251; 60760-782; 67877-614; 68071-5268; 70518-2210; 70771-1336; 71205-311; 71335-1016; 71335-1799; 0615-8360; 76420-228; 55111-179; 60505-0252; 60760-719; 63629-3209; 67877-613; 68788-7782; 70518-3181; 71610-162; 71610-455; 42291-808; 50090-0841; 63187-145; 63629-1673; 67296-1599; 70518-0133; 70518-1439; 70518-3112; 71610-167; 0615-8274; 0615-8469; 72789-326; 16714-172; 50090-0811; 50090-5767; 51655-603; 53002-1437; 68071-3440; 70518-0573; 72789-327; 76420-229; 43063-455; 55154-7287; 57664-503; 63629-2370; 68788-7781; 68788-7991; 16714-171; 71335-0914; 43353-167; 50268-759; 50268-760
UNII 6AI06C00GW
Synonyms tizanidine | 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole | Zanaflex | tizanidine hydrochloride | tizanidine monohydrochloride | DS 103-282 | Sirdalud
Chemical Information
Molecular Formula C9H8ClN5S
CAS Registry Number 51322-75-9
SMILES C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyelonephritis20.01.09.001; 11.01.14.002--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Respiratory acidosis22.02.02.004; 14.01.04.002--Not Available
Respiratory arrest22.02.01.0090.000078%Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.000078%Not Available
Retinal haemorrhage06.10.01.001; 24.07.05.003--Not Available
Rhabdomyolysis15.05.05.0020.000115%
Rhinitis22.07.03.006; 11.01.13.004--
Rhinorrhoea22.12.03.0210.000219%
Seizure17.12.03.0010.000167%
Sepsis11.01.11.003--
Shock24.06.02.0020.000287%Not Available
Sinus bradycardia02.03.03.0090.000287%
Sinus tachycardia02.03.03.0100.000131%
Sinusitis22.07.03.007; 11.01.13.005--
Skin cancer23.08.02.002; 16.03.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Skin ulcer24.04.03.007; 23.07.03.003--
Somnolence19.02.05.003; 17.02.04.0060.000695%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Stevens-Johnson syndrome11.07.01.005; 10.01.01.045; 23.03.01.007; 12.03.01.014--
Stupor19.02.05.004; 17.02.04.007--Not Available
Suicide attempt19.12.01.004--
Syncope17.02.04.008; 02.11.04.015; 24.06.02.0120.000209%
Tachycardia02.03.02.0070.000324%Not Available
Tension19.06.02.005--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
The 7th Page    First    Pre   7 8 9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene